A randomized study of the beneficial effects of aldosterone antagonism on lv function, structure, and fibrosis markers in metabolic syndrome

JACC: Cardiovascular Imaging

Volumn 4, Issue 12, 2011, Pages 1239-1249

  Kosmala, Wojciech ^a   Przewlocka Kosmala, Monika ^a   Szczepanik Osadnik, Hanna ^a   Mysiak, Andrzej ^a   O'Moore Sullivan, Trisha ^b   Marwick, Thomas H ^b,c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

collagen; echocardiography; hypertension; metabolic syndrome; obesity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; PLACEBO; PROCOLLAGEN TYPE 1 CARBOXY TERMINAL PROPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE; SULFONYLUREA; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; DIABETES MELLITUS; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GYNECOMASTIA; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMAGING SYSTEM; MALE; METABOLIC SYNDROME X; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TISSUE DOPPLER IMAGING; TREATMENT RESPONSE; ULTRASOUND TRANSDUCER;

AGED; ALDOSTERONE ANTAGONISTS; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, DOPPLER, COLOR; ECHOCARDIOGRAPHY, DOPPLER, PULSED; FEMALE; FIBROSIS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIUM; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SPIRONOLACTONE; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 83455172574     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2011.08.014     Document Type: Article

References (35)

1. C.Y. Wong, T. O'Moore-Sullivan, Z.Y. Fang, B. Haluska, R. Leano, T.H. Marwick Myocardial and vascular dysfunction and exercise capacity in the metabolic syndrome Am J Cardiol 96 2005 1686 1691 (Pubitemid 41790392)
2. L. de las Fuentes, A.L. Brown, S.J. Mathews Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass Eur Heart J 28 2007 553 559 (Pubitemid 47355514)
3. M. Chinali, G. de Simone, M.J. Roman Cardiac markers of pre-clinical disease in adolescents with the metabolic syndrome: the Strong Heart study J Am Coll Cardiol 52 2008 932 938
4. B. Aijaz, K.A. Ammar, F. Lopez-Jimenez, M.M. Redfield, S.J. Jacobsen, R.J. Rodeheffer Abnormal cardiac structure and function in the metabolic syndrome: a population-based study Mayo Clin Proc 83 2008 1350 1357
5. C. Voulgari, I. Moyssakis, A. Papazafiropoulou The impact of metabolic syndrome on left ventricular myocardial performance Diabetes Metab Res Rev 26 2010 121 127
6. E.S. Ford, W.H. Giles, W.H. Dietz Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey JAMA 287 2002 356 359 (Pubitemid 34251969)
7. S. Sciarretta, A. Ferrucci, G.M. Ciavarella Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome Am J Hypertens 20 2007 784 791 (Pubitemid 46951019)
8. A. Sato, T. Saruta Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy J Int Med Res 29 2001 13 21 (Pubitemid 32236891)
9. R.M. van de Wal, H.W. Plokker, D.J. Lok Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition Int J Cardiol 106 2006 367 372 (Pubitemid 41766640)
10. A.D. Struthers The clinical implications of aldosterone escape in congestive heart failure Eur J Heart Fail 6 2004 539 545 (Pubitemid 39070505)
11. M.I. Wahed, K. Watanabe, M. Ma Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy Pharmacology 73 2005 81 88 (Pubitemid 40082318)
12. T. Nishioka, M. Suzuki, K. Onishi Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation J Cardiovasc Pharmacol 49 2007 261 268 (Pubitemid 46855118)
13. T. Tsutamoto, A. Wada, K. Maeda Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure J Am Coll Cardiol 37 2001 1228 1233
14. C.G. Brilla, L.S. Matsubara, K.T. Weber Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism J Mol Cell Cardiol 25 1993 563 575 (Pubitemid 23208145)
15. P.M. Mottram, B. Haluska, R. Leano, D. Cowley, M. Stowasser, T.H. Marwick Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure Circulation 110 2004 558 565 (Pubitemid 39031173)
16. M. Tsukashita, A. Marui, T. Nishina Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery J Thorac Cardiovasc Surg 136 2008 58 64
17. H. Izawa, T. Murohara, K. Nagata Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study Circulation 112 2005 2940 2945 (Pubitemid 41612295)
18. M. Hayashi, T. Tsutamoto, A. Wada Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction Circulation 107 2003 2559 2565 (Pubitemid 36628936)
19. S.W. van den Borne, S. Isobe, H.R. Zandbergen Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling J Am Coll Cardiol Img 2 2009 187 198
20. F. Zannad, F. Alla, B. Dousset, A. Perez, B. Pitt Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES) Rales Investigators Circulation 102 2000 2700 2706
21. W. Iraqi, P. Rossignol, M. Angioi Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study Circulation 119 2009 2471 2479
22. F. Zannad, J.J. McMurray, H. Krum EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
23. J. Díez, C. Laviades Monitoring fibrillar collagen turnover in hypertensive heart disease Cardiovasc Res 35 1997 202 205 (Pubitemid 27372031)
24. J. Díez, C. Laviades, G. Mayor, M.J. Gil, I. Monreal Increased serum concentrations of procollagen peptides in essential hypertension Relation to cardiac alterations Circulation 91 1995 1450 1456
25. B. López, R. Querejeta, N. Varo Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients Circulation 104 2001 286 291 (Pubitemid 32666949)
26. K.F. Schulz, D.G. Altman, D. Moher CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials PLoS Med 7 2010 e1000251
27. S.M. Grundy, J.I. Cleeman, S.R. Daniels American Heart Association; National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement Circulation 112 2005 2735 2752 (Pubitemid 41532612)
28. R.M. Lang, M. Bierig, R.B. Devereux Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography J Am Soc Echocardiogr 18 2005 1440 1463 (Pubitemid 41821197)
29. R.B. Devereux, D.R. Alonso, E.M. Lutas Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings Am J Cardiol 57 1986 450 458 (Pubitemid 16119719)
30. E. Picano, G. Pelosi, M. Marzilli In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans Circulation 81 1990 58 64 (Pubitemid 20031767)
31. G.F. Watts, T.H. Marwick Ventricular dysfunction in early diabetic heart disease: detection, mechanisms and significance Clin Sci (Lond) 105 2003 537 540 (Pubitemid 37421645)
32. C.G. Brilla Renin-angiotensin-aldosterone system and myocardial fibrosis Cardiovasc Res 47 2000 1 3
33. C. Laviades, N. Varo, J. Díez Transforming growth factor beta in hypertensives with cardiorenal damage Hypertension 36 2000 517 522
34. V. Robert, J.S. Silvestre, D. Charlemagne Biological determinants of aldosterone-induced cardiac fibrosis in rats Hypertension 26 1995 971 978
35. V. Robert, N. Van Thiem, S.L. Cheav, C. Mouas, B. Swynghedauw, C. Delcayre Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension Hypertension 24 1994 30 36 (Pubitemid 24195401)